| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 9,142 | 23,371 |
| Amortization of intangible assets | 109 | 73 |
| Depreciation and amortization | 757 | 659 |
| Accretion of discounts on short-term investments | 1,487 | 851 |
| Stock-based compensation expense | 4,823 | 3,439 |
| Non-cash lease expense | -3,322 | -2,189 |
| Accounts receivable | -1,474 | -1,234 |
| Prepaid expenses and other assets | 368 | 1,076 |
| Accounts payable | -434 | -853 |
| Accrued liabilities and other long-term liabilities | -3,535 | -3,209 |
| Deferred revenue | -66,147 | -61,772 |
| Net cash used in operating activities | -52,344 | -36,796 |
| Purchases of property and equipment | 19 | 146 |
| Purchases of short term investments | 148,306 | 128,618 |
| Maturities of short-term investments | 103,000 | 83,000 |
| Net cash (used in) provided by investing activities | -45,325 | -45,764 |
| Proceeds from issuance of common stock, net of issuance costs | 93,373 | 93,373 |
| Proceeds from employee purchase plan and exercise of stock options | 430 | 177 |
| Net cash provided by financing activities | 93,803 | 93,550 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -3,866 | 10,990 |
| Cash and cash equivalents at beginning of period | 39,079 | - |
| Cash and cash equivalents at end of period | 35,213 | - |
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX)